Key Facts
Chief Executive Officer:
 Lamberto Andreotti
Headquarters:
 New York City
Business:
 Biopharmaceuticals
Web Address:
 www.bms.com
NYSE Listing:
 BMY
Net Sales:
 $19.5 billion in 2010
R&D Investment:
 $3.6 billion in 2010
2010 Largest-Selling Products:
PLAVIX®, $6.7 billion
ABILIFY®, $2.6 billion
REYATAZ®, $1.5 billion
AVAPRO®/AVALIDE®, $1.2 billion
SUSTIVA® franchise, $1.4 billion
BARACLUDE®, $931 million
Selected Key Products:
 ABILIFY® (aripiprazole)
ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate)
AVAPRO® (irbesartan)
BARACLUDE® (entecavir)
ERBITUX® (cetuximab)
IXEMPRA® (ixabepilone)
KOMBIGLYZE™ (saxagliptin and metformin)
NULOJIX® (belatacept)
ORENCIA® (abatacept)
ONGLYZA® (saxagliptin)
PLAVIX® (clopidogrel bisulfate)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUSTIVA® (efavirenz)
YERVOY™ (ipilimumab)
Principal Locations:
 Worldwide Facilities

Please click on the product links to see the Full Prescribing Information including Boxed WARNINGS for ABILIFY®, ATRIPLA®, BARACLUDE®, COUMADIN®, and NULOJIX®, Boxed WARNING for YERVOY™ regarding immune-mediated adverse reactions, Boxed WARNINGS for ERBITUX® regarding infusion reactions and cardiopulmonary arrest, and Boxed WARNINGS for AVAPRO® and AVALIDE® regarding use in pregnancy. As soon as pregnancy is detected, discontinue use of AVAPRO® or AVALIDE®.

Click here for trademark information on Bristol-Myers Squibb products.

721US11WA08601 06/11